Living Cell Technologies Limited (ASX: LCT) has executed a capital raise mandate with Alignment Capital Pty Ltd to raise up to approximately A$2.5M.
The raise is being undertaken by three distinct funding initiatives:
- a placement for A$750,000;
- a non-renounceable rights issue entitlement offer and shortfall offer by way of prospectus to raise circa A$1.2M; and
- a post rights issue over allotment offer to raise an additional A$562,500.
Firm commitments for the placement have been received by the company from professional and sophisticated investors of Alignment, representing 100M new shares priced at A$0.0075 per share for A$750,000.
LCT also intends to complete a non-renounceable rights issue entitlement offer. LCT will dispatch the rights issue prospectus to shareholders on the basis that shareholders may buy one new share in the company for every eight shares held at the record date for a subscription price of A$0.0075 per new share. Participants to the placement will not take part in the entitlement offer.
The indicative ex-date for the rights issue entitlement offer will be 5.00pm (AEST) on 22 March 2023. Alignment will have the first right of refusal to place any rights issue shortfall shares on a ‘best endeavours’ basis for the whole of the three months following the closure of the rights issue. If fully subscribed, the rights issue will result in the Company issuing approximately 160,670,465 new shares to raise approximately A$1.2M.
The funds raised from the placement and rights issue entitlement offer will be used to:
- further the development of the NTCELL project and third clinical trial for Parkinson’s disease,
- fund assessments of corporate development opportunities regarding additional projects, and
- provide for general working capital and costs associated with the capital raising initiative.
The funds, combined with existing cash reserves and an expected R&D rebate, will provide the company with a pro-forma cash position of approximately A$5M, establishing a strong financial base to support current and potential research and development initiatives.
We are thrilled with the ongoing support from our corporate advisor, Alignment Capital. The successful capital raise strengthens our financial footing, allowing us to advance the NTCELL program and explore complementary projects that align with our mission and capabilities, ultimately aimed at creating value for our stakeholders,” Executive Chairman, David Hainsworth, said.
